121 related articles for article (PubMed ID: 14623002)
1. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.
Nakayama K; Ishida Y; Ohtsuka M; Kawato H; Yoshida K; Yokomizo Y; Ohta T; Hoshino K; Otani T; Kurosaka Y; Yoshida K; Ishida H; Lee VJ; Renau TE; Watkins WJ
Bioorg Med Chem Lett; 2003 Dec; 13(23):4205-8. PubMed ID: 14623002
[TBL] [Abstract][Full Text] [Related]
2. MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization.
Nakayama K; Ishida Y; Ohtsuka M; Kawato H; Yoshida Ki; Yokomizo Y; Hosono S; Ohta T; Hoshino K; Ishida H; Yoshida K; Renau TE; Léger R; Zhang JZ; Lee VJ; Watkins WJ
Bioorg Med Chem Lett; 2003 Dec; 13(23):4201-4. PubMed ID: 14623001
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa.
Pan YP; Xu YH; Wang ZX; Fang YP; Shen JL
Arch Microbiol; 2016 Aug; 198(6):565-71. PubMed ID: 27060003
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?
Griffith DC; Corcoran E; Lofland D; Lee A; Cho D; Lomovskaya O; Dudley MN
Antimicrob Agents Chemother; 2006 May; 50(5):1628-32. PubMed ID: 16641428
[TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of putative efflux pump inhibitor/antibiotic combination treatments versus MDR strains of Pseudomonas aeruginosa in a Galleria mellonella in vivo infection model.
Adamson DH; Krikstopaityte V; Coote PJ
J Antimicrob Chemother; 2015 Aug; 70(8):2271-8. PubMed ID: 25921513
[TBL] [Abstract][Full Text] [Related]
6. An efflux pump (MexAB-OprM) of Pseudomonas aeruginosa is associated with antibacterial activity of Epigallocatechin-3-gallate (EGCG).
Kanagaratnam R; Sheikh R; Alharbi F; Kwon DH
Phytomedicine; 2017 Dec; 36():194-200. PubMed ID: 29157815
[TBL] [Abstract][Full Text] [Related]
7. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P
J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
[TBL] [Abstract][Full Text] [Related]
8. Expression of efflux pump MexAB-OprM and OprD of Pseudomonas aeruginosa strains isolated from clinical samples using qRT-PCR.
Arabestani MR; Rajabpour M; Yousefi Mashouf R; Alikhani MY; Mousavi SM
Arch Iran Med; 2015 Feb; 18(2):102-8. PubMed ID: 25644798
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.
Lomovskaya O; Warren MS; Lee A; Galazzo J; Fronko R; Lee M; Blais J; Cho D; Chamberland S; Renau T; Leger R; Hecker S; Watkins W; Hoshino K; Ishida H; Lee VJ
Antimicrob Agents Chemother; 2001 Jan; 45(1):105-16. PubMed ID: 11120952
[TBL] [Abstract][Full Text] [Related]
10. Resistance to beta-lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and beta-lactamase.
Nakae T; Nakajima A; Ono T; Saito K; Yoneyama H
Antimicrob Agents Chemother; 1999 May; 43(5):1301-3. PubMed ID: 10223959
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa.
Masuda N; Sakagawa E; Ohya S; Gotoh N; Tsujimoto H; Nishino T
Antimicrob Agents Chemother; 2000 Sep; 44(9):2242-6. PubMed ID: 10952562
[TBL] [Abstract][Full Text] [Related]
12. Linkage of the efflux-pump expression level with substrate extrusion rate in the MexAB-OprM efflux pump of Pseudomonas aeruginosa.
Narita S; Eda S; Yoshihara E; Nakae T
Biochem Biophys Res Commun; 2003 Sep; 308(4):922-6. PubMed ID: 12927807
[TBL] [Abstract][Full Text] [Related]
13. High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation.
Nakajima A; Sugimoto Y; Yoneyama H; Nakae T
Microbiol Immunol; 2002; 46(6):391-5. PubMed ID: 12153116
[TBL] [Abstract][Full Text] [Related]
14. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents.
Yoshida K; Nakayama K; Yokomizo Y; Ohtsuka M; Takemura M; Hoshino K; Kanda H; Namba K; Nitanai H; Zhang JZ; Lee VJ; Watkins WJ
Bioorg Med Chem; 2006 Dec; 14(24):8506-18. PubMed ID: 16979895
[TBL] [Abstract][Full Text] [Related]
15. Effect of sulbactam on anti-pseudomonal activity of beta-lactam antibiotics in cells producing various levels of the MexAB-OprM efflux pump and beta-lactamase.
Nakae T; Saito K; Nakajima A
Microbiol Immunol; 2000; 44(12):997-1001. PubMed ID: 11220688
[TBL] [Abstract][Full Text] [Related]
16. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
[TBL] [Abstract][Full Text] [Related]
17. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms.
Brooun A; Liu S; Lewis K
Antimicrob Agents Chemother; 2000 Mar; 44(3):640-6. PubMed ID: 10681331
[TBL] [Abstract][Full Text] [Related]
18. Conessine as a novel inhibitor of multidrug efflux pump systems in Pseudomonas aeruginosa.
Siriyong T; Srimanote P; Chusri S; Yingyongnarongkul BE; Suaisom C; Tipmanee V; Voravuthikunchai SP
BMC Complement Altern Med; 2017 Aug; 17(1):405. PubMed ID: 28806947
[TBL] [Abstract][Full Text] [Related]
19. Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
Sugimura M; Maseda H; Hanaki H; Nakae T
Antimicrob Agents Chemother; 2008 Nov; 52(11):4141-4. PubMed ID: 18676884
[TBL] [Abstract][Full Text] [Related]
20. The mode of action of 2-(thiazol-2-ylthio)-1beta-methylcarbapenems against Pseudomonas aeruginosa: the impact of outer membrane permeability and the contribution of MexAB-OprM efflux system.
Eguchi K; Ueda Y; Kanazawa K; Sunagawa M; Gotoh N
J Antibiot (Tokyo); 2007 Feb; 60(2):129-35. PubMed ID: 17420563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
